Last reviewed · How we verify
GenSci094
GenSci094 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.
GenSci094 is a recombinant human growth hormone analog designed to promote growth and metabolic effects. Used for Growth hormone deficiency, Growth disorders in pediatric patients.
At a glance
| Generic name | GenSci094 |
|---|---|
| Sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
| Drug class | Growth hormone analog |
| Target | Growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
GenSci094 functions as a growth hormone receptor agonist, binding to and activating growth hormone receptors to stimulate anabolic effects including increased protein synthesis, lipolysis, and linear growth. The drug is developed as a therapeutic option for growth hormone deficiency and related growth disorders.
Approved indications
- Growth hormone deficiency
- Growth disorders in pediatric patients
Common side effects
- Injection site reactions
- Headache
- Arthralgia
- Carpal tunnel syndrome
Key clinical trials
- Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
- To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (PHASE3)
- The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site (PHASE1)
- To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GenSci094 CI brief — competitive landscape report
- GenSci094 updates RSS · CI watch RSS
- Changchun GeneScience Pharmaceutical Co., Ltd. portfolio CI